CXCL9 and melanoma: Moreover, DNA-methylation inhibition increased CXCL9/CXCL10 secretion, overexpression of major histocompatibility complex class I/II antigens and components of the antigen-processing machinery, thus suggesting the augmentation of melanoma immunogenicity.